A global value dossier (GVD) represents an important tool for pharmaceutical manufacturer (PM) to consolidate information on considered disease, its management and treatment, epidemiology, as well as health economic outcomes. The current study intended to quantify the information that is transferable from a well prepared, comprehensive GVD to EUnetHTA submission via gap analysis.
PHP214
• Epidemiology data for all European countries; a thorough literature search should be carried out to obtain the data necessary • Management of the disease; a systematic search of guidelines, literature and registries should be completed • Clinical data; specific calculation and analysis need to be done for HTA purposes • Use of the technology; the potential harms should be described after search of official reports on drug safety
The most challenging gaps:
[1] EUnetHTA., 2014. http://www.eunethta.eu/
GAP ANALYSIS
• First, a gap analysis was performed to quantify the amount of missing information that could not be informed from an existing GVD
CLOSING MEASURES
• Then, potential measures to close the remaining gaps in the EUnetHTA dossier were evaluated and the optimal approach was carried out, such as identification of other drug specific sources of information and additional literature searches 
RESULTS
Graph 1: Sources used in completing EUnetHTA dossier
Graph 2a-d: Sources used in completing the 4 modules
A GVD can be a useful pool of knowledge for a new drug in a specific indication. However, a considerable part of information, which is required for a EUnetHTA submission will be missing even in far-reaching GVDs
Additional information required may be derived from existing clinical study reports, extensive systematic literature searches, internal sources and additional evaluations (epidemiological and quality of life studies, clinical data analysis) 1 2 3
Applying of validated and systematic methods during the GVD development process may reduce additional work for assessment reports
• Only 15.8% of the dossier could be completed with the information available from the GVD (Graph 1) • Most of the information required was retrieved from PM (internal documents, answers to authorities and clinical experts -35.4%) and the Clinical Study Report (CSR -22.7%) (Graph 1) • Nevertheless, 12.4% of the EUnetHTA dossier remained as Gaps, for which additional research would be needed (Graph 1) • The type of source used to complete the dossier differed for each of the four modules 
